Lamon K D
Department of Clinical Research and Regulatory Affairs, Rhône-Poulenc Rorer Central Research, Horsham, PA 19002.
Am Heart J. 1991 Feb;121(2 Pt 2):683-7. doi: 10.1016/0002-8703(91)90446-o.
The management of essential hypertension requires therapeutic selections that are not only effective in reducing diastolic blood pressure but are also tailored to the individual patient, with minimal effect on patient demographics, concurrent illnesses, and cardiovascular risk factors. Celiprolol hydrochloride is a new highly cardioselective vasodilating beta-adrenoceptor antagonist that has been proven effective and safe for the treatment of essential hypertension. It is comparable to other therapies in blood pressure control while demonstrating an excellent safety profile, favorable hemodynamic activity, and minimal effects on other cardiovascular risk factors. Celiprolol may offer the physician a unique therapeutic alternative.
原发性高血压的治疗需要选择不仅能有效降低舒张压，而且能根据个体患者量身定制的治疗方法，同时对患者的人口统计学特征、并发疾病和心血管危险因素影响最小。盐酸塞利洛尔是一种新型的高度心脏选择性血管舒张β-肾上腺素能受体拮抗剂，已被证明对原发性高血压的治疗有效且安全。在血压控制方面，它与其他疗法相当，同时具有出色的安全性、良好的血流动力学活性，并且对其他心血管危险因素影响极小。塞利洛尔可能为医生提供一种独特的治疗选择。
